Glesatinib (MGCD265) is an experimental anti-cancer drug.
It is in phase 2 clinical trials for non-small cell lung cancer (NSCLC).
It is a spectrum selective tyrosine kinase inhibitor "for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET".
See also Mirati Therapeutics
References
External links Definition of glesatinib - NCI Drug Dictionary - National Cancer Institute